Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
547 hedge funds and large institutions have $39.7B invested in Alexion Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 255 increasing their positions, 157 reducing their positions, and 84 closing their positions.
229% more funds holding in top 10
Funds holding in top 10: 7 → 23 (+16)
62% more repeat investments, than reductions
Existing positions increased: 255 | Existing positions reduced: 157
19% more capital invested
Capital invested by funds: $33.4B → $39.7B (+$6.31B)
3% less funds holding
Funds holding: 565 → 547 (-18)
15% less first-time investments, than exits
New positions opened: 71 | Existing positions closed: 84
65% less call options, than puts
Call options by funds: $164M | Put options by funds: $468M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$1.13B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$712M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$308M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$308M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$271M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$817M |
| 2 |
VOYA Investment Management
Atlanta,
Georgia
|
-$174M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$125M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$86.2M |
| 5 |
Prudential Financial
Newark,
New Jersey
|
-$70.5M |
ALXN Hedge Fund Activity: Q2 2015 in Review
547 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2015, worth a combined $39.7B — up 19% from $33.4B a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of ALXN and 71 opened new positions — a net loss of 13 holders — while 157 trimmed existing stakes and 255 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.13B. The largest seller was Fidelity Investments, cutting an estimated $817M.
- 547 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2015, down from 565 in Q1 2015.
- Funds reported $39.7B of Alexion Pharmaceuticals stock for Q2 2015, up 19% quarter-over-quarter.
- 71 funds opened new Alexion Pharmaceuticals positions in Q2 2015 and 84 closed out, a net change of -13 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2015 was Baker Bros. Advisors, an estimated $1.13B added.
- The largest Alexion Pharmaceuticals seller in Q2 2015 was Fidelity Investments, an estimated $817M sold.
Based on aggregated 13F filings for Q2 2015.